Analysts at HC Wainwright assumed coverage on shares of Inovio Pharmaceuticals (NASDAQ:INO) in a research note issued to investors on Thursday, AnalystRatings.com reports. The firm set a “buy” rating on the biopharmaceutical company’s stock.
The analysts wrote, “We note that ASF is highly contagious and the hemorrhagic viral disease is lethal and incurable in domestic and wild pigs. Within the past year, the ASF virus has spread from Europe to Asia countries, including China, Vietnam and Korea. Specifically, over 1M pigs have been culled and slaughtered in 2018, resulting in substantial economic losses. In our view, this partnership could bring Inovio additional upside in the animal health sector without any financial burden. In the wake of this update, we reiterate our Buy rating and $13 price target.””
Several other equities research analysts have also commented on the stock. Maxim Group restated a “buy” rating and issued a $8.00 price target on shares of Inovio Pharmaceuticals in a report on Wednesday, April 3rd. Zacks Investment Research raised shares of Inovio Pharmaceuticals from a “hold” rating to a “buy” rating and set a $5.25 price objective on the stock in a research report on Wednesday, January 16th. BidaskClub raised shares of Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, April 5th. Finally, Cantor Fitzgerald initiated coverage on shares of Inovio Pharmaceuticals in a research report on Monday, March 25th. They issued an “overweight” rating and a $3.62 price objective on the stock. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Inovio Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $7.57.
Shares of INO opened at $3.54 on Thursday. Inovio Pharmaceuticals has a 1-year low of $3.02 and a 1-year high of $6.30. The stock has a market cap of $349.98 million, a P/E ratio of -3.37 and a beta of 1.70. The company has a debt-to-equity ratio of 1.02, a current ratio of 4.92 and a quick ratio of 4.92.
Inovio Pharmaceuticals (NASDAQ:INO) last announced its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($0.30) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.01). Inovio Pharmaceuticals had a negative net margin of 295.24% and a negative return on equity of 97.95%. The company had revenue of $2.83 million for the quarter, compared to the consensus estimate of $4.44 million. Research analysts forecast that Inovio Pharmaceuticals will post -0.99 EPS for the current fiscal year.
Institutional investors have recently modified their holdings of the company. BlackRock Inc. grew its position in Inovio Pharmaceuticals by 1.7% during the 3rd quarter. BlackRock Inc. now owns 6,959,341 shares of the biopharmaceutical company’s stock worth $38,696,000 after purchasing an additional 114,003 shares during the last quarter. Dimensional Fund Advisors LP grew its position in Inovio Pharmaceuticals by 446.4% during the 3rd quarter. Dimensional Fund Advisors LP now owns 520,426 shares of the biopharmaceutical company’s stock worth $2,894,000 after purchasing an additional 425,188 shares during the last quarter. Renaissance Technologies LLC grew its position in Inovio Pharmaceuticals by 20.4% during the 3rd quarter. Renaissance Technologies LLC now owns 375,381 shares of the biopharmaceutical company’s stock worth $2,087,000 after purchasing an additional 63,700 shares during the last quarter. MetLife Investment Advisors LLC grew its position in Inovio Pharmaceuticals by 61.2% during the 3rd quarter. MetLife Investment Advisors LLC now owns 58,504 shares of the biopharmaceutical company’s stock worth $325,000 after purchasing an additional 22,207 shares during the last quarter. Finally, Teachers Advisors LLC grew its position in Inovio Pharmaceuticals by 9.1% during the 3rd quarter. Teachers Advisors LLC now owns 236,397 shares of the biopharmaceutical company’s stock worth $1,314,000 after purchasing an additional 19,748 shares during the last quarter. 40.50% of the stock is currently owned by hedge funds and other institutional investors.
Inovio Pharmaceuticals Company Profile
Inovio Pharmaceuticals, Inc, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of DNA-based immunotherapies and vaccines to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells, as well as is intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza.
Recommended Story: Relative Strength Index
Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.